Pelthos Therapeutics Inc. Selling, General and Administrative Expense
Pelthos Therapeutics Inc. (PTHS) reported Selling, General and Administrative Expense of $27.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- Pelthos Therapeutics Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $27.67M, a 918.89% increase year-over-year.
- Pelthos Therapeutics Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $21.10M, a 1186.83% increase year-over-year.
- Pelthos Therapeutics Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $18.47M, a 1100.06% increase year-over-year.
- Pelthos Therapeutics Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $19.63M, a 1101.22% increase year-over-year.
- Pelthos Therapeutics Inc. selling, general and administrative expense for fiscal 2025 was $42.45M, a 564.16% increase from fiscal 2024.
- Pelthos Therapeutics Inc. selling, general and administrative expense for fiscal 2024 was $6.39M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.67M 10-Q · filed 2026-08-13 | $48.78M 10-Q · filed 2026-08-13 | $67.25M derived: sum of 3 quarters · filed 2026-08-13 | $86.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $21.10M 10-Q/A · filed 2026-08-13 | $39.57M derived: sum of 2 quarters · filed 2026-08-13 | $59.20M derived: sum of 3 quarters · filed 2026-08-13 | $61.92M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $18.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $38.10M derived: sum of 2 quarters · filed 2026-03-19 | $40.81M derived: sum of 3 quarters · filed 2026-08-13 | $42.45M 10-K · filed 2026-03-19 |
| 2025-09-30 | $19.63M 10-Q · filed 2025-11-13 | $22.34M derived: sum of 2 quarters · filed 2026-08-13 | $23.98M 10-Q · filed 2025-11-13 | $25.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.72M 10-Q · filed 2026-08-13 | $4.36M 10-Q · filed 2026-08-13 | $5.89M derived: sum of 3 quarters · filed 2026-08-13 | $7.53M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.64M 10-Q/A · filed 2026-08-13 | $3.18M derived: sum of 2 quarters · filed 2026-08-13 | $4.81M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2024-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.17M derived: sum of 2 quarters · filed 2026-03-19 | $6.39M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $1.63M 10-Q · filed 2025-11-13 | $4.85M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |